Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 1 (1)
P 4 (1)

Trial Status

Active Not Recruiting1
Unknown1
Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT04881916Active Not RecruitingPrimary

Immune and Genomic Markers in ALK+ NSCLC

NCT05525338Phase 4Recruiting

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels

NCT04292119Phase 1Unknown

Lorlatinib Combinations in Lung Cancer

Showing all 3 trials

Research Network

Activity Timeline